期刊文献+

阿尔茨海默症治疗药物的研发现状和发展趋势 被引量:7

下载PDF
导出
摘要 阿尔茨海默症是一种持续性神经功能障碍,早期最显著的症状为健忘,通常表现为逐渐增加的短期记忆缺失,而长期记忆则相对不受病情的影响,随着病情的加重,病人的语言能力、空间辨别能力、认知能力会逐步衰退。
作者 郝博济
出处 《医学研究杂志》 2012年第10期9-12,155,共5页 Journal of Medical Research
  • 相关文献

参考文献14

  • 1吴思缈,周黎明.阿尔茨海默病的发病机制及药物治疗的进展[J].四川生理科学杂志,2009,31(1):36-39. 被引量:39
  • 2McKeage K. Spotlight on memantine in moderate to severe Alzheimer's disease[ J. Drugs & Aging,2010, 27(2) : 177 - 179. 被引量:1
  • 3Carrasco MM, Aguera L, Gil P, et al. Safety and effectiveness of done- pezil on behavioral symptoms in patients with Alzheimer disease [ J ]. Alzheimer Disease & Associated Disorders,2011, 25 (4) : 333 - 340. 被引量:1
  • 4Fujii A, Shinagawa R, Chatani Y, et al. Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease [ J ]. Folia Pharmacologica Japonica, 2012, 139 (1) : 26 -32. 被引量:1
  • 5Saint- Aubert L, Planton M, Hannequin D, et al. Amyloid imaging with AV45 ( 18F - fiorbetapir) in a cognitively normal AbetaPP dupli- cation carrier[ J ]. Journal of Alzheimer' s disease : JAD, 2012, 28 (4): 877-883. 被引量:1
  • 6Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild - to - moderate Alzheimer's disease[ J]. Expert Re- view of Clinical Immunology,2012, 8(2) : 135 - 149. 被引量:1
  • 7Panza F, Frisardi V, lmbimbo BP, et al. Anti - beta - arnyloid irnmu- notherapy for Alzheimer's disease: focus on bapineuzumab [ J ]. Cur- rent Alzheimer Research,2011, 8(8) : 808 -817. 被引量:1
  • 8Seo JS, Baek IS, Leem YH, et al. SK - PC - B70M alleviates neuro- logic symptoms in G93A - SOD1 amyotrophic lateral sclerosis mice [ J]. Brain Research ,2011, 1368 : 299 - 307. 被引量:1
  • 9Park SJ, Jung HJ, Son MS, et al. Neuroprotective effects of INM - 176 against lipopolysaccharide - induced neuronal injury [ J ]. Phar- macology Biochemistry and Behavior,2012, 101 (3) : 427 -433. 被引量:1
  • 10陈彪,马秋兰.阿尔茨海默病病因学研究进展及治疗展望[J].中华神经科杂志,2003,36(2):158-160. 被引量:56

二级参考文献82

共引文献122

同被引文献44

  • 1哈娜,哈力,杨习江.2种用药方案治疗阿尔茨海默病的经济学评价[J].中国药房,2011,22(14):1249-1251. 被引量:3
  • 2The United States Pharmacopoeial Convention. USP 35- NF30[S]. Rockville: the United States Pharmacopoeial Convention, 2012 : 2 967. 被引量:1
  • 3Society of Japanese Pharmacopueia. Japanese pharmaco- pueia[S].16 ed. Tokyo: The Ministry of Health, Labor and Welfare, 2011 : 745-747. 被引量:1
  • 4国家食品药品监督管理局.YBH02222003盐酸多奈哌齐片[S].2003-06-02. 被引量:1
  • 5国家食品药品监督管理局.YBH00822004盐酸多奈哌齐胶囊[S].2004-01-18. 被引量:1
  • 6国家食品药品监督管理局.YBH06682008盐酸多奈哌齐分散片[S].2008-06-08. 被引量:1
  • 7Sugimoto Hachiro, Tsuchiya Yutaka, Higurashi, et al. Cyclic amine compound, its use and pharmaceutical compositions comprising it: EP 0 296 560 A3 [ P ]. 1988. 被引量:1
  • 8Yoichi L, Toshihiko N, Masahiro S, et al. Preparation of aralkylpiperidines as acetylcholine esterase inhibi- tors : JP 09 268 176 [ P ]. 1997. 被引量:1
  • 9Saira M, Nath M R. Synthesis, isolation, and charac- terization of Donepezil open ring impurity [ J ]. Int J Pharm Pharm Sci, 2013,5 (3) : 826 - 829. 被引量:1
  • 10Saeed A, Ehsan S. An efficient synthesis of 8-hydroxy- 6,7 -dimethoxy-3 -methylisocoumarin (6-O-methylreticu- lol) [ J ]. Chemistry of Heterocyclic Compounds, 2005, 41( 11 ) :1381 - 1385. 被引量:1

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部